Genital Herpes Clinical Trial
Official title:
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of "AIC316 (Pritelivir)" 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.
Enrolled patients with Mucocutaneous genital HSV, will be randomized to receive either AIC326 or Valacyclovir first and then will be crossed over to receive the opposite Intervention. The study will consist of two treatment periods of 28 days separated by a washout period of 28 days. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06033261 -
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
|
Phase 1/Phase 2 | |
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Completed |
NCT00362297 -
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
|
Phase 4 | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT03831165 -
Melatonin Effects on Genital Herpes in Brazilian Women
|
Phase 4 | |
Completed |
NCT00262106 -
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
|
Phase 3 | |
Completed |
NCT01346475 -
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
|
Phase 4 | |
Completed |
NCT01390805 -
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
|
N/A | |
Terminated |
NCT03146403 -
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
|
Phase 2 | |
Completed |
NCT03080961 -
The VIBLOK SAfety and perFormancE Trial
|
N/A | |
Completed |
NCT00231049 -
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
|
Phase 1 | |
Completed |
NCT00306787 -
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
|
Phase 3 | |
Completed |
NCT00477334 -
Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
|
Phase 4 | |
Completed |
NCT00495573 -
HSV-2 Shedding Resolution After Acyclovir Treatment
|
N/A | |
Not yet recruiting |
NCT03595995 -
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
|
Phase 2 | |
Completed |
NCT01281007 -
Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
|
Phase 3 | |
Completed |
NCT01112956 -
Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2
|
N/A | |
Completed |
NCT00129818 -
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
|
Phase 4 | |
Completed |
NCT00808405 -
GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
|
N/A | |
Terminated |
NCT00495716 -
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
|
Phase 4 |